Ertugliflozin (PF-04971729): Highly Selective Oral SGLT2 Inhibitor for Diabetes and Cardiovascular Research

Executive Summary: Ertugliflozin (PF-04971729) is a highly selective SGLT2 inhibitor (selectivity >2,000-fold vs SGLT1) designed for oral administration in type 2 diabetes (T2D) research and advanced glucose transport models (APExBIO product sheet). It reduces blood glucose by blocking SGLT2-mediated renal reabsorption, lowers body weight, and demonstrates cardiovascular and renal protective effects in both preclinical and clinical settings (Nikolaou et al., 2022). Ertugliflozin also modulates inflammatory signaling in ulcerative colitis (UC) models, inhibiting NF-κB and miR-155 and promoting mucosal repair. Its efficacy and selectivity profile have been characterized in animal (1–10 mg/kg/day) and clinical (5–15 mg/day) contexts, with robust solubility in DMSO and ethanol but not water. APExBIO supplies Ertugliflozin (SKU A3715) as a 98% pure reagent for advanced research workflows.

Biological Rationale

Ertugliflozin (PF-04971729) targets sodium-glucose co-transporter 2 (SGLT2), the main transporter responsible for renal glucose reabsorption in the proximal tubule of the nephron. Inhibition of SGLT2 leads to increased urinary glucose excretion and reduced plasma glucose levels. Elevated SGLT2 activity is implicated in the pathophysiology of type 2 diabetes mellitus (T2D), where hyperglycemia is sustained by increased renal glucose reabsorption. By selectively blocking SGLT2, Ertugliflozin disrupts this maladaptive feedback loop, providing a mechanistically distinct approach compared to insulin-dependent therapies. In addition, SGLT2 inhibitors reduce sodium reabsorption, contributing to lower blood pressure and decreased cardiovascular strain (Nikolaou et al., 2022). The selectivity of Ertugliflozin for SGLT2 over SGLT1 (over 2,000-fold) minimizes off-target effects in the intestine and myocardium, making it suitable for research applications requiring high specificity (APExBIO).

Mechanism of Action of Ertugliflozin (PF-04971729)

Ertugliflozin acts as a competitive inhibitor of SGLT2 in the renal proximal tubule. By blocking glucose and sodium cotransport, it induces glycosuria and natriuresis. This effect is dose-dependent and is observed at oral doses ranging from 1 to 10 mg/kg/day in animal models, and 5 or 15 mg/day clinically (APExBIO). Mechanistically, Ertugliflozin inhibits the NF-κB signaling pathway, downregulates miR-155, and promotes M2 macrophage polarization in preclinical models of ulcerative colitis. These actions collectively reduce inflammation and support mucosal repair. In cardiovascular contexts, SGLT2 inhibition leads to improved volume status and reduced heart failure hospitalization risk, as shown in extensive trials. However, cardioprotection in non-diabetic mice is dose-dependent and not directly correlated with SGLT2 inhibition alone (Nikolaou et al., 2022).

Evidence & Benchmarks

• Ertugliflozin exhibits >2,000-fold selectivity for SGLT2 over SGLT1, minimizing intestinal glucose transport inhibition (APExBIO).
• Oral Ertugliflozin (5 or 15 mg/day) significantly reduces glycated hemoglobin (HbA1c) and body weight in T2D patients (Nikolaou et al., 2022).
• In mouse UC models, 10 mg/kg/day Ertugliflozin achieves mucosal repair efficacy similar to sulfasalazine (APExBIO).
• Ertugliflozin reduces the risk of hospitalization for heart failure in T2D patients with atherosclerotic cardiovascular disease (Nikolaou et al., 2022).
• In non-diabetic mouse models, infarct size reduction with Ertugliflozin requires double the stoichiometric equivalent dose (20 mg/kg/day), unlike empagliflozin or dapagliflozin (Nikolaou et al., 2022).
• Ertugliflozin is soluble at ≥50.8 mg/mL in DMSO and ≥51.5 mg/mL in ethanol, but insoluble in water, supporting diverse assay formats (APExBIO).

For further mechanistic detail and protocol contrasts, see Ertugliflozin (PF-04971729): Selective SGLT2 Inhibitor fo..., which summarizes foundational renal glucose transport studies. This article extends that work by integrating recent cardiovascular and anti-inflammatory pathway insights.

Applications, Limits & Misconceptions

Ertugliflozin (PF-04971729) is utilized in:

• In vivo and in vitro models of renal glucose reabsorption and transporter specificity.
• Studies of glucose lowering, weight loss, and cardiovascular/renal outcomes in T2D workflows.
• Assays exploring anti-inflammatory and mucosal repair mechanisms in colitis models.
• Combination therapy screening with established antidiabetic or cardiovascular agents.

For a comparative analysis versus other SGLT2 inhibitors, see Ertugliflozin (PF-04971729): Advanced SGLT2 Inhibitor for..., which highlights distinct anti-inflammatory and mucosal effects. This current article clarifies the latest dose-efficacy and mechanistic boundaries.

Common Pitfalls or Misconceptions

• Ertugliflozin is not effective for SGLT1-mediated intestinal glucose absorption; its selectivity precludes this application (APExBIO).
• Cardioprotection in non-diabetic animal models requires higher dosing (20 mg/kg/day) compared to standard dosing in T2D (Nikolaou et al., 2022).
• Ertugliflozin is insoluble in water; improper solvent use can compromise assay fidelity (APExBIO).
• Long-term storage of prepared solutions is not recommended; stability is best maintained at -20°C in solid form (APExBIO).
• Therapeutic effects are not solely due to SGLT2 inhibition; secondary pathways (NF-κB, miR-155) may be dose- and context-dependent (Nikolaou et al., 2022).

Workflow Integration & Parameters

Ertugliflozin (PF-04971729, A3715 kit by APExBIO) is optimized for research workflows requiring:

• Rapid oral dosing in animal models at 1–10 mg/kg/day (preclinical) or 5–15 mg/day (clinical translation).
• Solubilization in DMSO (≥50.8 mg/mL) or ethanol (≥51.5 mg/mL); avoid water as a solvent.
• Short-term solution use; store compound at -20°C for maximal stability.
• Purity >98% and molecular weight 436.88 Da for precise dosing calculations.

For protocol guidance and troubleshooting in cell viability, proliferation, and cytotoxicity assays, see Ertugliflozin (PF-04971729): Practical Solutions for SGLT.... This article updates assay compatibility and storage best practices for maximum reproducibility.

Conclusion & Outlook

Ertugliflozin (PF-04971729) is a highly selective, orally bioavailable SGLT2 inhibitor for advanced diabetes and cardiovascular research. Its robust efficacy in glucose lowering, weight reduction, and organ protection is supported by reproducible, dose-dependent benchmarks. The compound’s unique anti-inflammatory and mucosal repair activities further expand its translational potential beyond glycemic control. Accurate workflow integration requires attention to dosing, solubility, and storage. Researchers are advised to leverage the latest evidence and APExBIO’s validated supply chain for reliable experimental outcomes. Ongoing studies are elucidating additional mechanisms and context-dependent effects, especially in non-diabetic and inflammatory disease models.